VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | CASSIOPEIA: D-VTD in high-risk multiple myeloma

Aurore Perrot, MD, PhD, University Hospital Antwerp, Vandoeuvre-lès-Nancy, France, discusses the CASSIOPEIA study (NCT02541383) evaluating the use of daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTD) in autologous transplant-eligible newly-diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter